

SPH.L

Sinclair Pharma plc ("Sinclair" or "the Company")

Result of General Meeting

4 October 2010, Godalming, UK: Sinclair Pharma plc (the "Company" or "Sinclair": SPH:L), the international specialty pharma company, is pleased to announce that at a General Meeting of the Company held earlier today, the resolutions set out in the notice of general meeting annexed to the prospectus of the Company dated 17 September 2010, were duly passed without amendment.

The resolutions were passed on a show of hands. A breakdown of the proxies lodged prior to the General Meeting in respect of the resolutions is summarised below:

	<u>For</u>	<u>Against</u>	<u>Withheld</u>
Resolution 1	68,788,521	0	0
Resolution 2	68,788,521	0	0

Notes:

1. Any proxy arrangements which gave discretion to the Chairman have been included in the "For" totals.
2. A "vote withheld" is not a vote in law and is not counted in the calculation of the proportion of votes "for" or "against" a resolution.
3. The total number of votes cast by proxy was 68,788,521.
4. The issued share capital of Sinclair as at 4 October 2010 is 162,601,357 ordinary shares.

The results of the proxy votes lodged in advance of the General Meeting will be available on Sinclair's website www.sinclairpharma.com shortly.

In accordance with Sinclair's obligations under Listing Rule 9.6.2, copies of the resolutions passed have been submitted to the National Storage Mechanism and will shortly be available for viewing at www.hemscott.com/nsm.do.

It is expected that Admission of 67,857,131 New Ordinary Shares of 1 pence each will become effective on 6 October 2010 and that dealings in the New Ordinary Shares will commence at 8 a.m. on 6 October 2010.

For further information please contact:

Sinclair Pharma plc
Chris Spooner, CEO
Alan Olby, CFO

Tel: +44 (0)1483 410 600

Singer Capital Markets Ltd
Shaun Dobson
Claes Spång

Tel: +44 (0)20 3205 7500

Biddicks, Financial Public Relations
Shane Dolan

Tel +44 (0)20 7448 1000

About Sinclair Pharma Plc www.sinclairpharma.com

Sinclair Pharma plc is an international specialty pharmaceutical company providing solutions to treat wounds, dermatological and oral diseases through advanced surface technology and innovative delivery systems. It has a growing sales and marketing operation that is present in France, Italy, Germany and Spain, and an extensive marketing partner network across selected developed & emerging markets.

"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward-looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward-looking statements due to a variety of factors.